CN102872086B - The application of Houttuynoid A in treatment skin carcinoma medicine - Google Patents
The application of Houttuynoid A in treatment skin carcinoma medicine Download PDFInfo
- Publication number
- CN102872086B CN102872086B CN201210418598.7A CN201210418598A CN102872086B CN 102872086 B CN102872086 B CN 102872086B CN 201210418598 A CN201210418598 A CN 201210418598A CN 102872086 B CN102872086 B CN 102872086B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- application
- skin carcinoma
- medicine
- carcinoma medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the application of Houttuynoid A in preparation treatment skin carcinoma medicine, belong to technical field of new application of medicine.The present invention is found by external MTT antineoplastic activity evaluation, and Houttuynoid A also has significant inhibitory action to the growth of application on human skin JEG-3 A431, HME1, A375 and SK23.Therefore, Houttuynoid A for the preparation of anti-skin carcinoma medicine, can have good development prospect.Belong to first public for the purposes of the Houttuynoid A that the present invention relates in preparation treatment skin carcinoma medicine, because framework types belongs to brand-new framework types, and its inhibit activities for skin cancer cell is unexpectedly strong.
Description
Technical field
The present invention relates to the novelty teabag of compound H outtuynoid A, particularly relate to the application of Houttuynoid A in the anti-skin carcinoma medicine of preparation.
Technical background
Cancer is to one of maximum disease of human life's health hazard, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.74% is had to be natural product or derivatives thereof in antitumor drug, if paclitaxel and derivant thereof are exactly the current reasonable antitumor drug of effect clinically.Therefore, from natural product, anticancer compound is found or lead compound has great importance.
The compound H outtuynoid A that the present invention relates to is one and delivers (Chen in 2012, S.D.et al., 2012.Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletonsfrom Houttuynia cordata.Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S.D.etal., 2012.Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with NovelSkeletons from Houttuynia cordata.Organic Letters14 (7), 1772 – 1775.), the purposes of the Houttuynoid A that the present invention relates in preparation treatment skin carcinoma medicine is belonged to first public, because framework types belongs to brand-new framework types, and its inhibit activities for skin cancer cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for skin carcinoma obviously has significant progress.
Summary of the invention
The invention provides compound H outtuynoid A and prepare the application in antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid A in the anti-skin carcinoma medicine of preparation, and the structural formula of Houttuynoid A is as shown in formula I:
Formula I
The present invention is found by external MTT antineoplastic activity evaluation, and Houttuynoid A also has significant inhibitory action to the growth of application on human skin JEG-3 A431, HME1, A375 and SK23, suppresses the IC of this 4 strain Growth of Cells
50value is respectively 0.23 ± 0.02 μM, 0.13 ± 0.03 μM, 0.22 ± 0.07 μM and 0.17 ± 0.06 μM.Therefore, Houttuynoid A for the preparation of anti-skin carcinoma medicine, can have good development prospect.
The purposes of the Houttuynoid A that the present invention relates in preparation treatment skin carcinoma medicine belongs to first public, because framework types belongs to brand-new framework types, and its inhibit activities for skin cancer cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for skin carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound H outtuynoid A involved in the present invention is see document (Chen, S.D.et al., 2012.Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons fromHouttuynia cordata.Organic Letters14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid A tablet involved in the present invention:
Get 20 g of compound Houttuynoid A, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound H outtuynoid A capsule involved in the present invention:
Get 20 g of compound Houttuynoid A, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid A to the growth inhibited effect of application on human skin JEG-3
1. method: the cell being in growth logarithmic (log) phase: application on human skin JEG-3 A431, HME1, A375 and SK23(buy from Chinese Academy of Sciences's cell bank) with 1.5 × 10
4concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, the culture medium of the Houttuynoid A of 0.01 μM and 0.001 μM.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator cultivates 4h, then 100 μ L supernatants are sucked along culture fluid top, add 100 μ L DMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, 6 repeating holes are established in each process.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank× 100.
2. result: the growth of Houttuynoid A to application on human skin JEG-3 A431, HME1, A375 and SK23 has significant inhibitory action.This compound suppresses the IC of application on human skin JEG-3 A431, HME1, A375 and SK23 growth
50value is respectively: 0.23 ± 0.02 μM, 0.13 ± 0.03 μM, 0.22 ± 0.07 μM and 0.17 ± 0.06 μM.
Shown by above-described embodiment, the growth of Houttuynoid A of the present invention to application on human skin JEG-3 A431, HME1, A375 and SK23 has good inhibitory action.Prove thus, it is active that Houttuynoid A of the present invention has anti-skin carcinoma, can for the preparation of anti-skin carcinoma medicine.
Claims (1)
- The application of 1.Houttuynoid A in preparation treatment skin carcinoma medicine, described compound H outtuynoid A structure as formula Ishown in:formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418598.7A CN102872086B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid A in treatment skin carcinoma medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418598.7A CN102872086B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid A in treatment skin carcinoma medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872086A CN102872086A (en) | 2013-01-16 |
| CN102872086B true CN102872086B (en) | 2015-08-19 |
Family
ID=47473757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210418598.7A Expired - Fee Related CN102872086B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid A in treatment skin carcinoma medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872086B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127080A (en) * | 2012-10-25 | 2013-06-05 | 吴俊华 | Application of Aphanamixoid A in medicines curing skin cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100769654B1 (en) * | 2006-02-07 | 2007-10-23 | 인제대학교 산학협력단 | Composition comprising the extract of Houttuynia cordata for treating or prevening cancer disease |
-
2012
- 2012-10-27 CN CN201210418598.7A patent/CN102872086B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Chen,S.D. et al.Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《Organic Letters》.2012,第14卷(第7期),第1772-1775页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872086A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872086B (en) | The application of Houttuynoid A in treatment skin carcinoma medicine | |
| CN103463046B (en) | The application of Lycojaponicumin A in preparation treatment colorectal cancer medicine | |
| CN102872103B (en) | The application of Houttuynoid E in treatment medicine for nasopharyngeal | |
| CN103446088B (en) | The application of Incarviatone A in preparation treatment skin carcinoma medicine | |
| CN103446128B (en) | The application of Lycojaponicumin B in preparation treatment skin carcinoma medicine | |
| CN103463044B (en) | The application of Lycojaponicumin A in preparation treatment skin carcinoma medicine | |
| CN103405420B (en) | The application of Chukrasone B in preparation treatment medicine for nasopharyngeal | |
| CN103405447B (en) | The application of Chukrasone A in preparation treatment medicine for nasopharyngeal | |
| CN103446133B (en) | The application of Lycojaponicumin B in preparation treatment tongue cancer drug | |
| CN103463069B (en) | The application of Lycojaponicumin C in preparation treatment medicine for nasopharyngeal | |
| CN103446141B (en) | The application of Lycojaponicumin C in preparation treatment tongue cancer drug | |
| CN103479633B (en) | The application of Lycojaponicumin B in preparation treatment medicine for nasopharyngeal | |
| CN103463056B (en) | The application of Lycojaponicumin A in preparation treatment tongue cancer drug | |
| CN103405451B (en) | The application of Chukrasone A in preparation treatment tongue cancer drug | |
| CN103446089B (en) | The application of Incarviatone A in preparation treatment medicine for nasopharyngeal | |
| CN103446146B (en) | The application of Lycojaponicumin C in preparation treatment blindgut cancer | |
| CN103463054B (en) | The application of Lycojaponicumin A in preparation treatment bladder cancer medicine | |
| CN103446122B (en) | The application of Lycojaponicumin B in preparation treatment carcinoma of prostate medicine | |
| CN103463024B (en) | The application of Lycojaponicumin B in preparation treatment renal carcinoma medicine | |
| CN103463072B (en) | The application of Lycojaponicumin C in preparation treatment bladder cancer medicine | |
| CN103479630B (en) | The application of Lycojaponicumin A in preparation treatment breast cancer medicines | |
| CN103405444B (en) | The application of Chukrasone A in preparation treatment bladder cancer medicine | |
| CN103462964B (en) | The application of Incarviatone A in preparation treatment cancer of biliary duct medicine | |
| CN103463045B (en) | The application of Lycojaponicumin A in preparation treatment blindgut cancer | |
| CN103463020B (en) | The application of Lycojaponicumin A in preparation treatment renal carcinoma medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |